Zumutor has developed multiple expression platforms which lead to improvement of antibody dependent cellular cytotoxicity of therapeutic antibodies. The ADCC Improvement Platform and methods of development are unique and we have filed patent applications to secure global IP rights. All R &D activities related to our ADCC Improvement Platform are carried out in our facilities in India
Glycan-engineering with our proprietary ADCC Improvement Platform will lead to antibody products with enhanced efficacy
Higher efficiency in tumor cell death
Greater efficacy at lesser number of tumour antigens
Glycan engineering of monoclonal antibody would lead to stronger interaction with NK cell CD16 receptors; this unique property could be used in NK cell mediated therapeutics in immuno-oncology targets, and CAR engineered NK cell therapy
Zumutor’s Glycoengineered Antibody
We have successfully developed AntiHer2 Antibody using our in house ADCC Improvement Platform in our R & D Lab in India. The new product has been tested for multiple analytical assays to compare with commercially available Trastuzumab innovator molecule and potentially breakthrough results have been observed
Equivalent Her2/Neu antigen binding affinity when compared with Trastuzumab.
Analysis of major glycans in the glycoengineered AntiHer2 Antibody product
ADCC improvement – 20 times higher ADCC compared to Trastuzumab.
Zumutor’s glycoengineered Anti Her2 Antibody is ready for animal studies. Necessary regulatory permissions are being sought.
Zumutor Biologics Inc. is a niche, innovation driven biologics company registered in the state of Delaware, with its office in Woburn, MA. Expertise and acumen of the Zumutor team is focused on development of new products through patent-pending technology platforms in our state of the art R&D facility in India
Zumutor also offers differentiated services ranging from co-development of monoclonal antibodies to recombinant technology based biosimilars